Business
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase ® Technologies Inc. (T...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex VirusToronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral candidate, Ruvidar®, in the destruction of Herpes Simplex Virus Type 1 (\"HSV-1\").The latest preclinical data was published in MDPI - Viruses titled, \"Ruvidar®-An Effective Anti-Herpes Simplex Virus Agent\" and is available for viewing at:Website: https://www.mdpi.com/1999-4915/17/9/1280PDF Version: https://www.mdpi.com/1999-4915/17/9/1280/pdfThis peer-reviewed publication provides strong support that Ruvidar® is more effective in the treatment of HSV-1 than either Acyclovir® or Metformin®, even without light-activation. Acyclovir® and its derivatives are currently known as the gold standard treatment for HSV-1.1According to this latest research, Acyclovir® and Metformin® had little, if any, effect on the virus, once infection was established; however, Ruvidar® was able to have a dramatic inhibitory effect, post infection, without light-activation. In other words, in a normal human infection setting (onset of a cold sore lesion), using acyclovir or metformin had no beneficial effects; whereas, Ruvidar® remained highly effective in suppressing viral replication in cells that harbored active infection. Ruvidar®'s protection extended to preventing non-infected cells from contracting an HSV-1 infection, which minimized the spread of the disease to adjacent cells and if used clinically would help minimize patient duration of the disease.In further research, Ruvidar® was shown to be effective in the treatment of Acyclovir®-resistant HSV-1 mutants. This would be highly beneficial for patients who are prone to cold sore lesions that have grown resistant to treatment with acyclovir.This research underscores Ruvidar®'s potential as a next-generation antiviral therapy, capable of addressing both standard and drug-resistant HSV-1...